cyrilzakka/clinical-trials huggingface dataset:
COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV

This observational study will prospectively characterize the long-term symptoms and side effects of COVID-19 in cohorts of people living with and without HIV. This will be achieved through a series of remote study visits involving completing surveys about health history, symptoms, mood, quality of life and changes in health, and up to two blood draws from home through the use of a mobile phlebotomy service.

This is a prospective observational study being conducted to learn about late (2+ weeks or more) effects of COVID-19 in people living with and without HIV. The investigators plan to do this by studying people who have COVID-19 and people who have not had COVID-19, and by studying people living with HIV and people who are HIV-negative. The investigators will investigate the average duration of symptoms after COVID-19, how these symptoms affect quality of life, and what medical complications are common after COVID-19 in people with and without HIV.

Participation involves:

* Participant completion of surveys about themselves, their health history, their quality of life and mood in the recent past, and about COVID-19 or HIV if the participant has a history of either infection. The investigators will ask participants to answer questions in up to 5 follow-up surveys over the course of a year about their symptoms, mood, quality of life, and changes in health. Participants will also complete a series of short tests of thinking, memory, and reaction speed at certain follow-up surveys.
* Up to two visits to the participant's home (or an acceptable location of their choosing) by a phlebotomist. The phlebotomist will collect about 3.5 tablespoons of blood, as well as measure height, weight, and vital signs when laying down and standing up.

This is a fully remote study and all study activities can be done from home or another location of the participant's choosing.

Eligibility Criteria:
Inclusion Criteria:

* Adults 18 years of age or older
* Living within the contiguous 48 states
* Groups 1 and 3: self-reported HIV infection
* Groups 2 and 4: self-reported HIV negative

Exclusion Criteria:

* Inability to communicate by telephone in English or Spanish
* Inability to complete required study events
* A first or only diagnosis of COVID-19 5 or more weeks prior to first contact with participant
* Groups 3 and 4: diagnosis of cOVID-19 ever, or participant suspects they had COVID-19 at any time regardless of whether they were tested
Ultrasonography-guided and Surgical Rectus Sheath Block in Single-port Access Laparoscopy

Rectus sheath block is effective in reducing pain in the peri-umbilical region, and the use of ultrasonography is recommended to perform the block at the precise location. Recently, intra-operative rectus sheath block has also been introduced without the aid of ultrasonography. However, no study has not yet compared the analgesic effects of these two different approaches (ultrasonography-guided vs direct surgical). Thus, the aim of our study is to compare the effect of ultrasonography-guided and direct-surgical rectus sheath block after single-port access laparoscopy in benign ovary cyst patients.

This is a randomized, prospective study comparing the analgesic effects of ultrasonography-guided and direct-surgical rectus sheath block after single-port access laparoscopy in benign ovary cyst patients.

Patients will be randomly divided into 3 groups based on the procedure: control group, ultrasonography group and direct injection group. Each group consists of 30 patients.

* Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.

  * Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.

    * Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.

Analgesic efficiency will be assessed using the VAS (visual analogue scale) pain scale and the total amount of self-administered fentanyl via PCA (patient controlled analgesia) devices at multiple time scales (1, 6, 10, 24 and 48 hours after surgery). We will also compare the incidence of fentanyl complications, such as nausea, vomiting, pruritus and dizziness

Eligibility Criteria:
Inclusion Criteria:

1. Patients scheduled for a single port laparoscopic surgery at Chung Nam University hospital due to benign tumor of the ovary or the fallopian tube
2. Between age of twenty to seventy
3. Patients with a physical rating of 1 or 2 according to the American Anesthesiology guidelines
4. Patients who have not had laparoscopic surgery within two months

Exclusion Criteria:

1. Hysterectomy via single port laparoscopic surgery
2. Patients with chronic pelvic pain
3. Abdominal pain of unknown origin
4. Suspected malignant tumor
5. Diagnosed with malignant tumor of any origin
6. Patients currently taking psychiatric medicine
7. Pregnancy
8. Patients with a history of hypersensitivity to amide type local anesthetics
9. Patients with a history of hypersensitivity to opioid
10. Risk of bleeding
11. Unable to comprehend or does not agree to the consent form
Prevalence and Association of Anxiety and Sleep Disturbances Among Medical Students.

Observational, Cross-sectional study

It was a cross-sectional study conducted in December 2024 with the consent of 200 undergraduate medical students of a tertiary care hospital affiliated medical college, who qualified as per the inclusion criteria.

Inclusion criteria:

All the students of MBBS Phase-II.

Exclusion criteria:

Students with prior diagnosed Sleep disorders Students with prior diagnosed co-morbidities Students unable/unwilling to answer the question.

Eligibility Criteria:
Inclusion criteria:

- All the students of MBBS Phase-II.

Exclusion criteria:

* Students with prior diagnosed Sleep disorders
* Students with prior diagnosed co-morbidities
* Students unable/unwilling to answer the question.
A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea

The purpose of this study is to evaluate the safety by determining the incidence rates of all adverse events (AEs) including serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not reflected on the precaution in the use, ADRs already known, non-serious ADRs and other safety related information (laboratory values changes, etc).

This is a long-term prospective, observational post-marketing surveillance study of azilsartan medoxomil in participants with essential hypertension. This study will assess the safety and effectiveness of azilsartan medoxomil prescribed as a monotherapy or taken concomitantly with other anti-hypertension therapies in real-world clinical practice settings.

The study will enroll approximately 3000 participants. The data will be prospectively collected, at the centers from medical files and recorded into electronic case report forms (e-CRFs). All the participants will be assigned to a single observational cohort:

* Participants With Essential Hypertension

The multi-center study will be conducted in South Korea. Data collection will be based on routinely scheduled and emergency visits over the surveillance period, scheduled at Visit 1 (Baseline), Visit 2 (6 Weeks), Visit 3 (3 Months or more less than 6 Months) and Visit 4 (6 Months or more \[Month 9\]). The overall duration of the study will be approximately 6 years. All participants will be followed up for 9 months after drug administration.

Eligibility Criteria:
Inclusion Criteria:

1. With Essential Hypertension.

   * Newly diagnosed with essential hypertension or who have no long-term history of hypertension medication after diagnosis (The participant has a SBP or DBP \>=140 or 90 mmHG, respectively).
   * Receiving treatment with other hypertension medications.
2. Newly prescribed and initiates azilsartan medoxomil for the treatment of hypertension, as a monotherapy or taken concomitantly with other anti-hypertension therapies.

Exclusion Criteria:

1. Treated with azilsartan medoxomil outside of the locally approved label in South Korea.
2. With known hypersensitivity or presence of any contraindication to azilsartan medoxomil.
3. Use of aliskiren in combination with azilsartan medoxomil in participants with diabetes or with moderate to severe renal impairment (glomerular filtration rate \[GFR \] \< 60 milliliter per minute \[mL/min\]/1.73 m\^2).
Urell and Pregnancy

Evaluation of the effect of URELL consumption on the occurrence of recurrent urinary tract infection (Acute cystitis, pyelonephritis and asymptomatic bacteriuria).


Eligibility Criteria:
Inclusion Criteria:

- Pregnant woman in her 4th gestational month or more, having urinary tract infection.

Exclusion Criteria:

* Pregnant woman with organic or functional urinary tract malformations
* Diabetic patients
* HIV positive
Prognostic Factors Affecting Duchenne Muscular Dystrophy

Determination of prognostic factors affecting ambulation of duchenne muscular dystrophy

Duchenne muscular dystrophy is the most common herditary muscular disease , it lead to loss of ambulation in early teenageers . It lead to early death at the mean age of 19 years

Eligibility Criteria:
Inclusion Criteria:

* any male pt diagnosed as duchenne muscular dystrophy by typical clinical picture \&shooting serum CPK level \&EMG study or biopsy \& age 10 to 18yrs old

Exclusion Criteria:

* female patient ' age below 10 yrs old or above 18 yrs old .patient with autoimmune disease or malignancy
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of progressive advanced or metastatic (tumor that has spread) solid tumors
* No tumor spread to the brain
* Feeling well other than cancer diagnosis (i.e. lab work, no infection, etc.)
* Available tumor tissue sample from prior surgery
* 4-6 weeks since prior therapy and recovered from prior therapy
* Men and women, ages 18 and above
* Women must not be pregnant or breastfeeding
* Diagnosis of advanced or metastatic (tumor that has spread) colorectal, hepatocellular (liver) or renal (kidney) cancer
* Measurable disease on scans (at least one)
Cord Blood Alarin Levels in Term Babies

In this study, alarin levels in the cord blood of babies with large birth weights will be compared with babies of normal weight. Thus, the investigators aimed to find out whether there is a relationship between babies' birth weights and alarin.

Studies have shown that the galanin neuropeptide family plays a role in regulating appetite, insulin resistance, obesity, hypertension and metabolism. Alarin is a peptide consisting of 25 amino acids. Current research shows that allerin plays an important role in the emergence and development of diabetes and obesity. There are studies that found that the serum alarin level increased significantly in patients with impaired glucose tolerance and type 2 diabetes mellitus. Additionally, studies have found that both non-obese and obese type 2 diabetes mellitus serum alarin levels increase.

Studies in the literature are related to adults, and there are no studies on alarin levels in newborn babies.

Based on the alarin studies available in the literature, the investigators determined whether there is a relationship between the alarin level and the baby's birth weight by comparing the alarin level in the cord blood of babies with a high birth weight according to their gestational age (both babies of diabetic mothers and babies of non-diabetic mothers) compared to babies whose birth weight is within the normal range. the investigators aimed to find it.

Eligibility Criteria:
Inclusion Criteria:

* Babies given consent by their families
* Healthy babies

Exclusion Criteria:

* Babies with syndromic appearance or any accompanying disease
* Babies whose family does not give consent
Beneficial Effects of Lactobacillus Reuteri DSM 17938 Supplementation on Asthmatic Children

Objective The aim of the trial is to evaluate the beneficial effects of the oral administration of the probiotic L. Reuteri (Reuterin®) on the airways allergic inflammation in children with mild to moderate persistent asthma.

Study design This is a randomized, double-blind, placebo controller trial. 50 children will be enrolled (age range 6-14 years), affected by mild to moderate persistent asthma based on the GINA Guidelines and allergic to acarus (Dermatophagoides farinae and D. pteronyssinus ++/+++). At the enrollment period all children have to show asthmatic symptoms and to be under antileukotrienes treatment (Montelukast 5mg/die) based on the GINA Guidelines. Any inhaling corticosteroids therapies have to be stopped 8 weeks before the trial beginning.

Patients will be randomly divided into 2 treatment groups:

Group A: 25 patients will take antileukotrienes + L. reuteri drops (108 CFU = 5 drops daily).

Group B: 25 patients will take antileukotrienes + placebo. At the enrollment period (T0), after the 1st and the 2nd month of supplementation (T1 and T2), and also 1 month after the supplementation end (T3), all patients will be clinically evaluated through spirometry, FeNO determination and exhale condensate analysis.

During the entire trial period the number of asthmatic exacerbations and the use of beta-2 antagonists will be monitored by a diary properly examined at T1, T2 and T3.

All children will be enrolled at the Asthma and Infant Respiratory Physiopathology unit "Michele Miraglia del Giudice" of the "F. Fede" Pediatric Department.

The analysis of the inflammatory markers on the exhaled condensate will be performer at T1, T2 and T3 in the Pharmacology unit of the Experimental Medicine Department.

During the trial it will be possible to administer only salbutamole MDI if it needed. If patients will be administered with any systemic corticosteroids they will exit from the trial.

At the enrolment period all patients will receive the completed information on the trial and the informed consent will be properly signed.


Eligibility Criteria:
Inclusion Criteria:

* Children with age range 6-14 years
* Informed consent signed

Exclusion Criteria:

* Participation to other clinical trials
* Informed consent not signed
Safety And Efficacy Study Of Topic Mucopolysaccharide Polysulfate In The Superficial Varicose Veins Treatment

Evaluate the safety, tolerability and effectiveness of mucopolysaccharide polysulfate in the treatment of superficial varicose veins


Eligibility Criteria:
Inclusion Criteria:

* Patients must be able to understand the study procedures, agree to participate, and give written consent.
* Patients must be able to follow the study medication regimen.
* Patients with inflammatory process in superficial veins for more than 72 hours.
* Presence of symmetric lesions to compare one side to the other.

Exclusion Criteria:

* Pregnancy or risk of pregnancy.
* Lactation.
* Use of topical or systemic anti-inflammatory, antihistamine or immunosuppressive drugs within the last 48 hours prior to the study
* Any alteration at other deep veins.
* History of atopy or allergic diseases.
* History of allergy to any component of the formulations.
* Other conditions considered by the investigator as reasonable for non-eligibility.
S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease

RATIONALE: Studying the chromosomes in samples of bone marrow and blood in the laboratory from patients with cancer or other blood diseases may help doctors learn more about the disease.

PURPOSE: This laboratory study is analyzing chromosomes in patients with newly diagnosed multiple myeloma or other blood disease.

OBJECTIVES:

* Compare the frequency of deletion 13 as detected by fluorescence in situ hybridization (FISH) and conventional cytogenetics in patients with newly diagnosed multiple myeloma (MM) or other monoclonal gammopathies (MG).
* Examine the prognostic value of specific subsets of chromosome aberrations detected by conventional cytogenetics and FISH in relation to event-free and overall survival in these patients.
* Compare the prognostic value of cytogenetics and FISH with other MM and MG prognostic factors in these patients.
* Correlate the presence of cytogenetic and FISH features with clinical pathophysiological, cellular, or other molecular characteristics in these patients.

OUTLINE: Patients receive treatment as directed by the treatment clinical trial on which they are registered. Patients undergo bone marrow or blood sample collection periodically for conventional cytogenetic analysis and fluorescence in situ hybridization studies (FISH). Samples are analyzed for deleted 13q/monosomy 13 and chromosomal abnormalities.

PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Diagnosis of 1 of the following:

  * Multiple myeloma (MM)
  * Smoldering myeloma
  * Waldenstrom's macroglobulinemia (WM)
  * Monoclonal gammopathy of undetermined significance (MGUS)
  * Amyloidosis (AL)
* Newly diagnosed disease
* Must be currently registered, but have not begun therapy, on 1 of the following Southwest Oncology Group (SWOG) treatment clinical trials:

  * SWOG-S0115
  * SWOG-S0232
  * SWOG-S0340
  * All new SWOG coordinated MM, smoldering myeloma, WM, MGUS, or AL clinical trials activated on or after the activation date of this research study (SWOG-S0334)

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
Reflexology on Seizure Frequency, Fatigue, Stress and Sleep Quality in Epilepsy Patients

Epilepsy is among the diseases that cause loss of neurological abilities regardless of any trauma. Reflexology is one of the complementary therapies based on activating the body's self-healing power through special hand techniques applied to the feet. It is known that there are positive changes in seizure frequency, fatigue, stress and sleep quality in epilepsy patients after reflexology. This study will be conducted to determine the effect of reflexology on seizure frequency, fatigue, stress and sleep quality in epilepsy patients.

Individual interviews were conducted with epilepsy patients who applied to the neurology clinic of a university hospital where the research was conducted, and patients who met the inclusion criteria and agreed to participate in the study will be randomly included in the experiment.

Patients arriving on the first day of the week will be placed in the experimental group. In the following days, groups will be formed as one day experiment and one day control (Monday-experiment, Tuesday-control, Wednesday-experiment, Thursday-control, Friday-experiment). Data collection tools will be applied to the experimental and control group patients at the beginning and end of the study. Only reflexology massage will be applied to the experimental group, and no application will be applied to the control group. Data will be collected simultaneously with the control and experimental groups.

Eligibility Criteria:
Inclusion Criteria:

* Knowing the diagnosis of the disease
* Having not received reflexology therapy before
* Being literate in Turkish
* Conscious Open,
* Able to communicate verbally,
* Being 18 years or older

Exclusion Criteria:

* Pain starts while doing massage,
* Having an infection,
* High fever,
* Having clot problems in the leg veins,
* Having an acute (newly developing) disease (heart attack, fainting, etc.),
* Wounds in the application area,
* Patients in the first 3 months of pregnancy.
* Paraplegia or thrombosis
* Leg varicose veins or foot disease (open wound or fracture on the foot)
* Diagnosis of psychiatric disorder or dementia
Dissecting the Mechanism of DNA Methylation on the Invasiveness of Pituitary Tumors.

DNA methylation is one of the important ways of protein post-translational modification.Pituitary adenoma (PA) is a benign neuroendocrine tumor that originates from adenohypophysial 45 cells, and accounts for 10%-20% of all primary intracranial tumors. However some PAs can present with high invasiveness and irregular growth, which tend to compresses the optic chiasm and third ventricle, encase the internal carotid artery, and affect hormone secretion from the pituitary gland and hypothalamus. In this study we focus on the mechanism of DNA methylation on the invasiveness of pituitary tumors.


Eligibility Criteria:
Inclusion Criteria:

* 1) histologically confirmed PAs, 2) Non-function pituitary adenomas

Exclusion Criteria:

* 1) Associated with other tumors or serious underlying diseases, 2) the medical records were not complete, or the follow-up data were missing.
Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery

The investigators are attempting to compare the anticoagulant (blood thinning) effects of a recently FDA approved medication, Rivaroxaban, in people who have undergone gastric bypass surgery to people who have not had this surgery. It is thought that gastric bypass may alter the absorption of this medication, but this has not been previously studied.

The investigators will study the anticoagulant effect of rivaroxaban in healthy volunteers who are in one of four groups

1. Non obese people who have not had a gastric bypass.
2. Obese people who have not had a gastric bypass
3. People who have had a gastric bypass
4. People who are planning to undergo gastric bypass surgery in the near future who are willing to be studied before and after the bypass.

The study will involve taking a single low dose of rivaroxaban and multiple blood samples will be taken over the next 24 hours and the effect of rivaroxaban on blood clotting will be measured using the prothrombin time and an anti-factor Xa assay. The effects of rivaroxaban will be compared between the different groups.


Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers in one of four groups

  1. Normal weight and not having prior gastric bypass surgery,
  2. Obese and not having prior gastric bypass surgery,
  3. Subjects with prior roux en Y gastric bypass surgery,
  4. Obese and planning to undergo roux en Y gastric bypass

Exclusion Criteria:

* Active renal or liver disease,
* bleeding diathesis,
* concurrent treatment with anticoagulants or aspirin,
* indication for aspirin or anticoagulant treatment,
* gastrointestinal bleeding,
* uncontrolled hypertension,
* active malignancy,
* anemia,
* thrombocytopenia,
* pregnant,
* allergy to rivaroxaban,
* coagulopathy or any other medical condition that would increase risk to the subject